ArticleCureus2025
Risperidone-Induced Paradoxical Agitation in a Child With Lamb-Shaffer Syndrome, Autism Spectrum Disorder, and Attention Deficit Hyperactivity Disorder: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lamb-Shaffer syndrome (LAMSHF) is a rare autosomal dominant neurodevelopmental disorder caused by haploinsufficiency of the SOX5 gene on chromosome 12p12.1 and characterized by global developmental delay, intellectual disability, speech and language impairment, and frequent behavioral disturbances, including autistic traits and attention deficits. Data on psychotropic response profiles in Lamb-Shaffer syndrome are extremely limited. We report a six-year-five-month-old boy with de novo Lamb-Shaffer syndrome, autism spectrum disorder (ASD) of mild-to-moderate severity, attention deficit hyperactivity disorder, and query intellectual disability who developed paradoxical behavioral activation after initiation of very low-dose risperidone oral solution (0.12 mg once daily) for mild-to-moderate irritability, aggression, and self-injurious head banging. Shortly after treatment initiation, he exhibited marked agitation, increased hyperactivity, worsening aggression and self-injury, insomnia, restlessness, amplification of stereotypic movements, emotional lability, and prolonged crying episodes, clearly exceeding his baseline behavioral pattern and temporally associated with dosing. Clinical assessment and available laboratory investigations, including complete blood counts, liver and renal function tests, electrolytes, thyroid function, bone profile, vitamin B12, vitamin D, lactate, and ammonia, did not reveal metabolic, endocrine, or infectious etiologies. Risperidone was discontinued with subsequent resolution of the paradoxical symptoms and return to baseline. He was then switched to aripiprazole (2 mg once daily for 10 days, then 5 mg once daily), with gradual moderate-to-marked improvement in irritability and self-injurious behavior and no recurrence of agitation over several months of follow-up. To our knowledge, this is the first reported case of risperidone-induced paradoxical activation in a child with Lamb-Shaffer syndrome. This case highlights the need for cautious antipsychotic use and close monitoring in rare genetic neurodevelopmental disorders and suggests that aripiprazole may represent a viable alternative when risperidone is poorly tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.